Brian Hubbard, Anji Pharmacetuticals CEO

Look­ing to rewrite the rules of drug li­cens­ing, start­up An­ji is on the hunt for 'dy­nam­ic eq­ui­ty' joint ven­tures

Li­cens­ing is one of the most com­mon ways big drug­mak­ers lever­age biotech in­no­va­tion to dri­ve gains across their pipelines — and the struc­ture of those deals is pret­ty well es­tab­lished. But one biotech with home bases in Chi­na and the US thinks it may have a bet­ter way.

On Tues­day, Cam­bridge-based biotech An­ji Phar­ma closed a $70 mil­lion Se­ries B with two late-stage mol­e­cules in the fold and a mis­sion to rewrite the rules of drug li­cens­ing through what it calls “dy­nam­ic eq­ui­ty” deals and a joint ven­ture-heavy game plan. The round was fund­ed in whole by Chi­nese hedge fund CR Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.